Research

Optic neuritis (inflammation of the optic nerve) is a common side-effect of multiple sclerosis (MS) and leads to many sight-related difficulties, including blurriness, impaired colour recognition and problems...

Filmed during our MSBase Feature Week, this short video with Associate Professor Helmut Butzkueven introduces PrevANZ, a Multiple Sclerosis Research Australia led study investigating the role Vitamin D...

Dr Vilija Jokubaitis et al Natalizumab (Tysabri) is an antibody used for the treatment of multiple sclerosis (MS). It is currently the strongest drug available for the treatment of MS, however, it has also...

MSBase is an international multiple sclerosis (MS) registry that is helping answer many questions about MS. In this short video, Associate Professor Helmut Butzkueven (neurologist, MS researcher) explains...

Dr Tomas Kalincik et al Relapses of MS activity present with worsening of neurological symptoms and are usually followed by periods of stability. These are a defining feature of relapsing-remitting MS, the...

The first Google Hangout gave members of our community an opportunity to chat with MS researcher and MStranslate co-founder, Brett...

By Brett Drummond Recently, we had a member of our community ask us whether there was a link between Type 1 diabetes (T1D) and MS. In response, here is a short summary of what is currently known on the...

By Brett Drummond It is generally accepted that multiple sclerosis is an autoimmune disease, that is, a disease that arises from the body’s own immune system attacking and destroying the myelin sheath that...

CCSVI was a contentious topic of debate within the MS community throughout 2013, and we have worked hard to provide balanced, unbiased coverage of the discussion. In line with this approach, we thank Kerri...

Often, we post stories on our social media pages that outline potential new multiple sclerosis therapies in different phases of clinical development. Here, we discuss what happens at each phase in the process...